Literature DB >> 10229080

Human anti-FcepsilonRIalpha autoantibodies isolated from healthy donors cross-react with tetanus toxoid.

M P Horn1, T Gerster, B Ochensberger, T Derer, F Kricek, M H Jouvin, J P Kinet, T Tschernig, M Vogel, B M Stadler, S M Miescher.   

Abstract

Natural antibodies (Ab) reacting with self antigens have been shown to be present in all individuals. These autoantibodies (auto-Ab) can be either pathogenic or non-pathogenic. Auto-Ab reacting with the alpha-subunit of the high-affinity receptor for IgE (FcepsilonRIalpha) have been implicated in the pathogenesis of a subset of patients with chronic idiopathic urticaria (CIU). Intravenous immunoglobulin (IVIg) preparations have been used with variable clinical benefit in the treatment of these patients. Here we show that anti-FcepsilonRIalpha auto-Ab are present in a therapeutic IVIg preparation as well as in atopic and chronic urticaria patients and healthy individuals. We affinity-purified the anti-FcepsilonRIalpha Ab from an IVIg preparation using recombinant FcepsilonRIalpha. Interestingly, these anti-FcepsilonRIalpha auto-Ab showed no evidence of histamine release but strongly cross-reacted with an external antigen, tetanus toxoid (TTd) with a higher affinity for TTd than for the FcepsilonRIalpha. Since the cross-reacting Ab are non-anaphylactogenic, there is no evidence that TTd immunization may contribute to the pathogenesis of CIU. However, our results may indicate that the anti-FcepsilonRIalpha auto-Ab belong to the natural Ab and serve as the parental Ab for some anti-TTd Ab.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229080     DOI: 10.1002/(SICI)1521-4141(199904)29:04<1149::AID-IMMU1149>3.0.CO;2-H

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  [Autoreactive urticaria and autoimmune urticaria].

Authors:  M Maurer; M Metz; M Magerl; F Siebenhaar; P Staubach
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

2.  Detection of anti-glutamic acid decarboxylase antibodies in immunoglobulin products.

Authors:  Tukisa D Smith; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2017-06-29

3.  Evaluation of chronic urticaria in patients with Hashimoto thyroiditis.

Authors:  A A Kandeel; M Zeid; T Helm; M A Lillie; E Donahue; J L Ambrus
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

Review 4.  Autoimmunity in chronic urticaria and urticarial vasculitis.

Authors:  D C Napoli; T M Freeman
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

Review 5.  Autoimmune urticaria.

Authors:  Malcolm Greaves
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

6.  Progress and challenges in the understanding of chronic urticaria.

Authors:  Marta Ferrer; Allen P Kaplan
Journal:  Allergy Asthma Clin Immunol       Date:  2007-03-15       Impact factor: 3.406

Review 7.  Chronic urticaria: recent advances.

Authors:  Malcolm W Greaves; Kian Teo Tan
Journal:  Clin Rev Allergy Immunol       Date:  2007-09-18       Impact factor: 8.667

8.  A rapid method of detecting autoantibody against FcεRIα for chronic spontaneous urticaria.

Authors:  Mey-Fann Lee; Tzu-Mei Lin; Szu-Wei Liu; Yi-Hsing Chen
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

9.  Mimicry of human IgE epitopes by anti-idiotypic antibodies.

Authors:  M Vogel; S Miescher; S Kuhn; A W Zürcher; M B Stadler; C Ruf; F Effenberger; F Kricek; B M Stadler
Journal:  J Mol Biol       Date:  2000-05-19       Impact factor: 5.469

Review 10.  Immunological events in chronic spontaneous urticaria.

Authors:  Marta Ferrer
Journal:  Clin Transl Allergy       Date:  2015-08-25       Impact factor: 5.871

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.